C 16 H 10 F 2 N 2 O 3 , monoclinic, P21/c (no. 14), a = 9.4647(7) Å,
. 
Source of material
The title compound was synthesized according to a reported procedure [6] . A mixture of 4-hydroxy-6-methylpyran-2-one (10 mmol), 3,4-di uorobenzaldehyde (10 mmol), malononitrile (10 mmol) and 4-(dimethylamino)pyridine (DMAP) (1 mmol) in ethanol (100 mL) was re uxed for 2-3 h and then cooled to room temperature. After ltering the precipitates, they were sequentially washed with icy water and ethanol and then dried under a vacuum.
Experimental details
H atoms bonded to C and N were positioned geometrically and re ned using a riding model, with C-H = 0.93 Å and N-H = 0.86 Å with U iso (H) = 1.
times Ueq(C) or Ueq(N).

Discussion
Pyrans have a variety of pharmacological and biological activities including antitumor, analgesic and ulcerogenic, anti-in ammatory, anticoagulant, phototriggering, and fungicidal properties, moreover, they can be used as anticoagulants in the production of pesticides [1, 2] . In particular, the antitumor activity of pyran compounds has received considerable attention because of their cytotoxic activity against numerous types of cancers, including malignant melanoma, leukemia, renal cell carcinoma, prostate and breast cancer cell progression [3] [4] [5] .
In the crystal structure of the title compound, the 4H-pyran ring is nearly planar and the adjacent ring with the keto group adopts an almost planar conformation. The 4H-pyran ring plane is almost perpendicular to the plane of the di uorophyenyl moiety. All bond lengths and angles are in the expected ranges.
